skip to Main Content

Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

Newsfeed image, light gray text on dark gray background
Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) immune checkpoint blockade with chemotherapy could overcome these barriers.

Here we present results of a phase Ib trial combining ipilimumab and gemcitabine in advanced PDAC. Read more . . . 

Back To Top